. Author manuscript; available in PMC: 2009 Jul 1.

Published in final edited form as: Toxicol Sci. 2008 Apr 15;104(1):218–227. doi: 10.1093/toxsci/kfn079

Table 2.

Disruption of Keap1 and CDDO-Im pretreatment inhibits hepatic inflammation following ConA administration^a.

Genotype or Pre-treatment	Treatment	Macrophages^b	Neutrophils^b	Ifnγ^c	Tnfα^c	Mip-2^c	Mcp-1^c
cKeap1-WT	Veh	2.6 ± 0.2	1.6 ± 0.1	16.0 ± 5.2	10.2 ± 0.6	102.3 ± 56. 7	29.1 ± 3.9
cKeap1-WT	ConA	19.2 ± 1.9 ^*	14.5 ± 0.5 ^*	16.0 ± 5.2	10.2 ± 0.6	102.3 ± 56. 7	29.1 ± 3.9

cKeap1-KO	Veh	2.6 ± 0.2	1.7 ± 0.2	1.4 ± 0.4 ^**	2.8 ± 1.3 ^**	1.4 ± 0.7 ^**	2.7 ± 1.2 ^**
cKeap1-KO	ConA	8.1 ± 0.2 ^{^}	2.4 ± 0.4	1.4 ± 0.4 ^**	2.8 ± 1.3 ^**	1.4 ± 0.7 ^**	2.7 ± 1.2 ^**

Nrf2-WT + Veh	Veh	3.2 ± 0.2	1.0 ± 0.1	18.2 ± 5.4	26.0 ± 3.3	286.6 ± 87.5	66.1 ± 10.6
Nrf2-WT + Veh	ConA	16.3 ± 1.2 ^*	8.1 ± 0.7 ^*	18.2 ± 5.4	26.0 ± 3.3	286.6 ± 87.5	66.1 ± 10.6

Nrf2-WT + CDDO-Im	Veh	2.5 ± 0.3	0.9 ± 0.1	1.5 ± 0.4 ^¶	2.5 ± 0.6 ^¶	1.1 ± 0.2 ^¶	2.4 ± 0.3 ^¶
Nrf2-WT + CDDO-Im	ConA	4.8 ± 0.3 ^{^}	1.1 ± 0.2	1.5 ± 0.4 ^¶	2.5 ± 0.6 ^¶	1.1 ± 0.2 ^¶	2.4 ± 0.3 ^¶

Livers were harvested 24-hr following ConA administration. Values represent the mean ± SE (Nrf2-WT, N = 5; cKeap1-KO/ cKeap1-WT; N = 3)

Data are expressed as cells/field

Gene transcript levels are expressed as relative fold-change (ConA/Veh)

p < 0.05 compared to all groups within genotype, ANOVA-SNK multiple comparisons

^{^}

p < 0.05 compared to ConA treated group within genotype, ANOVA-SNK multiple comparisons

^**

p < 0.05 compared to cKeap1-WT, Student’s t-test

^¶

p < 0.05 compared to Nrf2-WT + Veh, Student’s t-test